Aquestive Therapeutics (AQST) Operating Income (2017 - 2025)
Historic Operating Income for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$11.5 million.
- Aquestive Therapeutics' Operating Income fell 3846.8% to -$11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.8 million, marking a year-over-year decrease of 16437.47%. This contributed to the annual value of -$30.8 million for FY2024, which is 10375.45% down from last year.
- As of Q3 2025, Aquestive Therapeutics' Operating Income stood at -$11.5 million, which was down 3846.8% from -$11.4 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Operating Income peaked at $55000.0 during Q2 2024, and registered a low of -$19.4 million during Q1 2025.
- Over the past 5 years, Aquestive Therapeutics' median Operating Income value was -$8.9 million (recorded in 2022), while the average stood at -$8.7 million.
- Its Operating Income has fluctuated over the past 5 years, first soared by 10130.67% in 2024, then plummeted by 2076909.09% in 2025.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Operating Income stood at -$11.7 million in 2021, then grew by 8.19% to -$10.7 million in 2022, then surged by 63.49% to -$3.9 million in 2023, then crashed by 247.2% to -$13.6 million in 2024, then increased by 15.47% to -$11.5 million in 2025.
- Its last three reported values are -$11.5 million in Q3 2025, -$11.4 million for Q2 2025, and -$19.4 million during Q1 2025.